stars 1 stars 2 stars 3

The AlphaVax pipeline is targeting pandemic influenza and cytomegalovirus (CMV), as well as grant and collaborator-supported programs in HIV, prostate and breast cancer, and several biodefense vaccines. Clinical data from the first alphavaccine human trials have confirmed safety and immunological activity in man. These immune responses are characterized as robust and balanced antibody (B-cell) and cellular (T-cell) immune responses, confirming the promising data we have obtained in over a decade of intensive pre-clinical work with this vector platform.

AlphaVax Questions

The AlphaVax annual revenue was $14 million in 2026.

Karen Scappaticci is the Director of AlphaVax.

2 people are employed at AlphaVax.

The NAICS codes for AlphaVax are [325, 32541, 32, 325414, 3254].

The SIC codes for AlphaVax are [283, 28].

Top AlphaVax Employees

View Similar People
G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users